KRAS and neoplasm: To expand upon their translational potential, we characterized the PDXs response to radiotherapy, demonstrated tumor growth inhibition with MEK inhibition in KRAS mutated PDXs and showed significant growth delay with the MET inhibitor savolitinib in a PDX harboring a MET exon 14 mutation.